A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination With Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer

Trial Profile

A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination With Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer

Suspended
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Efatutazone (Primary) ; Paclitaxel
  • Indications Thyroid cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jun 2017 Status changed from recruiting to suspended in the Scheduled Interim Monitoring.
    • 14 Nov 2016 Planned number of patients changed from 50 to 20.
    • 28 Oct 2016 Status changed from suspended to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top